Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dendritic cell gene therapy.

Mark Onaitis1, Matthew F Kalady, Scott Pruitt

  • 1Department of Surgery, Surgical Oncology Section, Duke University Medical Center 3118, Durham, NC 27710, USA.

Surgical Oncology Clinics of North America
|December 19, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting Ferroptosis to Overcome Radioresistance and Enhance Immunotherapy in Colorectal Cancer.

Cells·2026
Same author

Breslow Thickness and Microsatellite Detection in Primary Cutaneous Melanoma: Implications for Oncologic Surgeons and Patients.

The American surgeon·2026
Same author

Instability in Pentanucleotide Markers in a Subset of Microsatellite Instability-High Colorectal Cancer.

Current oncology (Toronto, Ont.)·2026
Same author

The Need for Individualized Decision-Making for Neoadjuvant Therapy in Advanced Colon Cancer.

JAMA surgery·2026
Same author

A history of the collaborative group of the Americas on inherited gastrointestinal cancer (CGA-IGC): 1995-2025.

Familial cancer·2026
Same author

A Critical Appraisal of Colorectal Surgery Fellowship Standardized Letters of Recommendations Using Objective Criteria.

Diseases of the colon and rectum·2026
Same journal

Small Incisions, Big Impact-Robotic Surgery Is Revolutionizing Cancer Care.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive and Robotic Surgery for Cancer.

Surgical oncology clinics of North America·2026
Same journal

TeleSurgery: The Present and the Future for Minimally Invasive and Robotic Surgery.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive and Robotic Surgery for Rectal Cancer.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive/Robotic Surgery for Colon Cancer.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery in Liver Transplantation.

Surgical oncology clinics of North America·2026
See all related articles

Future dendritic cell (DC) cancer vaccines require optimized delivery methods and maturation protocols. Careful monitoring of both immune and clinical responses is crucial for advancing DC-based cancer immunotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Dendritic cell (DC) based cancer vaccines represent a promising area of research.
  • Current challenges include optimizing DC delivery, maturation, and response monitoring.
  • Existing studies highlight the need for further investigation into these critical aspects.

Purpose of the Study:

  • To review key areas requiring advancement for the field of DC-based cancer vaccines.
  • To discuss the impact of delivery methods and DC maturation on vaccine efficacy.
  • To highlight the importance of standardized methods for monitoring treatment responses.

Main Methods:

  • Review of various studies investigating DC administration routes (intradermal, subcutaneous, intranodal, intravenous).
  • Analysis of studies comparing immature versus mature DC use in cancer vaccination.

Related Experiment Videos

  • Examination of diverse methods for assessing patient immune and clinical responses to DC vaccines.

    • Main Results:

    • Intradermal and intralymphatic DC delivery routes appear more effective in inducing Th1 responses compared to intravenous.
    • DC maturation influences antigen processing, homing to lymph nodes, and T cell responses.
    • Current methods for monitoring vaccine response (e.g., DTH, tetramers, ELISpot, chromium release) have limitations.

    Conclusions:

    • Optimizing DC delivery routes and maturation status is essential for enhancing vaccine efficacy.
    • Standardized and comprehensive monitoring of both immunological and clinical outcomes is necessary.
    • Further rigorous research and careful clinical application are required to advance DC-based cancer immunotherapy.